Charts
4576:デ・ウエスタン・セラピテクス研究所
Remove from History
Add to History
諸事情によりHistoryの登録はログインユーザーに限定。
Current:
67.0
PreviousClose:
69.0
Open:
69.0
High:
69.0
Low:
66.0
Dividend History None
EPS:
-11.91
BPS:
24.499
ROA:
-21.9%
ROE:
-55.8%
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; and DWR-2206, a regenerative medicine cell-product for bullous keratopathy. D. Western Therapeutics Institute, Inc. was founded in 1999 and is headquartered in Nagoya, Japan.